Cindy Motz
Stock Analyst at Goldman Sachs
(0.41)
# 3,069
Out of 4,416 analysts
23
Total ratings
17.65%
Success rate
-17.86%
Average return
Main Sectors:
Top Industries:
8 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MPLN MultiPlan | Maintains: Neutral | $5.5 → $2.05 | $0.67 | +207.95% | 2 | Nov 16, 2022 | |
| MDRX Veradigm | Upgrades: Buy | $22 → $23 | $7.70 | +198.70% | 2 | Nov 9, 2022 | |
| HQY HealthEquity | Upgrades: Neutral | $64 → $77 | $79.75 | -3.45% | 2 | Oct 21, 2022 | |
| ACCD Accolade | Maintains: Buy | $15 → $16 | $7.26 | +120.39% | 5 | Oct 7, 2022 | |
| SHCR Sharecare | Maintains: Neutral | $1.5 → $2.1 | $0.74 | +182.90% | 3 | Sep 21, 2022 | |
| HCAT Health Catalyst | Maintains: Buy | $29 → $18 | $6.48 | +177.78% | 3 | Aug 10, 2022 | |
| DOCS Doximity | Maintains: Buy | $53 → $46 | $24.09 | +90.95% | 3 | Aug 8, 2022 | |
| TDOC Teladoc Health | Downgrades: Neutral | $55 → $36 | $12.78 | +181.69% | 3 | Jul 28, 2022 |
MultiPlan
Nov 16, 2022
Maintains: Neutral
Price Target: $5.5 → $2.05
Current: $0.67
Upside: +207.95%
Veradigm
Nov 9, 2022
Upgrades: Buy
Price Target: $22 → $23
Current: $7.70
Upside: +198.70%
HealthEquity
Oct 21, 2022
Upgrades: Neutral
Price Target: $64 → $77
Current: $79.75
Upside: -3.45%
Accolade
Oct 7, 2022
Maintains: Buy
Price Target: $15 → $16
Current: $7.26
Upside: +120.39%
Sharecare
Sep 21, 2022
Maintains: Neutral
Price Target: $1.5 → $2.1
Current: $0.74
Upside: +182.90%
Health Catalyst
Aug 10, 2022
Maintains: Buy
Price Target: $29 → $18
Current: $6.48
Upside: +177.78%
Doximity
Aug 8, 2022
Maintains: Buy
Price Target: $53 → $46
Current: $24.09
Upside: +90.95%
Teladoc Health
Jul 28, 2022
Downgrades: Neutral
Price Target: $55 → $36
Current: $12.78
Upside: +181.69%